KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Equity Ratio (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Equity Ratio data on record, last reported at 0.35 in Q3 2025.

  • For Q3 2025, Equity Ratio rose 2.43% year-over-year to 0.35; the TTM value through Sep 2025 reached 0.35, up 2.43%, while the annual FY2024 figure was 0.34, 3.9% up from the prior year.
  • Equity Ratio reached 0.35 in Q3 2025 per JAZZ's latest filing, up from 0.34 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.56 in Q1 2021 and bottomed at 0.26 in Q3 2022.
  • Average Equity Ratio over 5 years is 0.34, with a median of 0.32 recorded in 2024.
  • Peak YoY movement for Equity Ratio: crashed 42.42% in 2021, then rose 17.81% in 2023.
  • A 5-year view of Equity Ratio shows it stood at 0.32 in 2021, then decreased by 11.67% to 0.28 in 2022, then increased by 15.17% to 0.33 in 2023, then rose by 3.9% to 0.34 in 2024, then rose by 2.29% to 0.35 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.35 in Q3 2025, 0.34 in Q2 2025, and 0.36 in Q1 2025.